NCT03196804View on ClinicalTrials.gov

A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126.

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 7, 2017

Primary Completion Date

November 15, 2017

Study Completion Date

November 15, 2017

Conditions
Healthy
Interventions
DRUG

LC28-0126

LC28-0126

DRUG

Placebo

Placebo

Trial Locations (1)

110-744

Seoul National University Hospital, Clinical Trial Center, Seoul

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT03196804 - A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126. | Biotech Hunter | Biotech Hunter